Staphylococcus aureus and antibiotic resistance;Staphylococcus aureus ve antibiyotik direnci

Mikrobiyoloji Bulteni

Volumn 45, Issue 3, 2011, Pages 565-576

  Sancak, Banu ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Methicillin resistance; Novel antibiotics; Staphylococcus aureus; Vancomycin resistance

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DRUG DERIVATIVE; LINEZOLID; MINOCYCLINE; OXAZOLIDINONE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; QUINUPRISTIN-DALFOPRISTIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; DRUG EFFECT; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; REVIEW; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; OXAZOLIDINONES; PROTEIN SYNTHESIS INHIBITORS; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VANCOMYCIN; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 80052489962     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Culos KA, Cannon JP, Grim SA. Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Am J Ther 2011 [Epub ahead of print] PubMed PMID: 21642833.
2. Ippolito G, Leone S, Lauria FN, Nicastri E, Wenzel RP. Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis 2010; 14(Suppl 4): S7-11.
3. Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care 2009; 15(5): 403-12.
4. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46(2): 193-200. (Pubitemid 351269157)
5. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13(3): 222-35. (Pubitemid 46603352)
6. Stefani S, Goglio A. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. Int J Infect Dis 2010; 14(Suppl 4): S19-22.
7. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358(9277): 207-8. (Pubitemid 32718546)
8. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40(7): 1058-60. (Pubitemid 40418318)
9. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13(3): 222-35. (Pubitemid 46603352)
10. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol 2008; 8(6): 747-63.
11. International Working Group on the Classification of Staphylococcal Cassette Chromosome (SCC) Elements (IWG-SCC). www.sccmec.org
12. Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008; 27(1): 3-15. (Pubitemid 350197870)
13. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62(Suppl 1): i1-9.
14. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45(Suppl 3): S171-6. (Pubitemid 47378903)
15. Rehm SJ, Tice A. Staphylococcus aureus: methicillin-susceptible S.aureus to methicillin-resistant S.aureus and vancomycin-resistant S.aureus. Clin Infect Dis 2010; 51(Suppl 2): S176-82.
16. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40(1): 135-6. (Pubitemid 27341646)
17. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340(7): 493-501. (Pubitemid 29093284)
18. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351(9110): 1212. (Pubitemid 28171844)
19. Hanaki H, Hososaka Y, Yanagisawa C, et al. Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan. J Infect Chemother 2007; 13(2): 118-21. (Pubitemid 46669291)
20. de Lassence A, Hidri N, Timsit JF, et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006; 42(2): 170-8. (Pubitemid 43054186)
21. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23(1): 99-139.
22. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55(1): 405-10.
23. th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006, San Francisco. Washington DC: American Society for Microbiology; Abstract C2-1160.
24. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hasçelik C. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56(3): 519-23. (Pubitemid 41264130)
25. Gould IM. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2011; 66(Suppl 4): iv17-21.
26. McAleese F, Wu SW, Sieradzki K, et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- 5. oureus-type resistance to vancomycin. J Bacteriol 2006; 188(3): 1120-33. (Pubitemid 43146428)
27. Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010; 10(5): 516-21.
28. Cui L, Iwamoto A, Lian JQ, et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50(2): 428-38. (Pubitemid 43190949)
29. th Informational Supplement, Document M100-S20, 2010. CLSI Wayne, PA.
30. Walsh TR, Bolmström A, Qwärnström A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39(7): 2439-44. (Pubitemid 32606216)
31. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9(10): 617-24.
32. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011; 37(3): 219-24.
33. Moreillon P. New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect 2008; 14(Suppl 3): 32-41.
34. Gold HS, Pillai SK. Antistaphylococcal agents. Infect Dis Clin North Am 2009; 23(1): 99-131.
35. Jones RN, Fritsche TR, Sader HS, Ross JE. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007; 59(3): 309-17. (Pubitemid 350016703)
36. Luh KT, Hsueh PR, Teng LJ, et al. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000; 44(12): 3374-80.
37. Dogruman-Al F, Akça G, Aykan B, Sipahi AB, Çaǧlar K. Metisiline dirençli Staphylococcus aureus suşlarinda kinupristin/dalfopristin, linezolid duyarliliklari ve makrolit-linkozamit- streptogramin B direnci. Infeksiyon Derg 2008; 22(3): 153-63.
38. Öksüz L, Gürler N. Klinik örneklerden izole edilen metisiline dirençli stafilokok suşlarinin son yillarda kullanima giren antibiyotiklere in vitro duyarliliǧi. ANKEM 2009; 23(2): 71-7.
39. Efe S, Sinirtas M, Ozakin C. In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains. Mikrobiyol Bul 2009; 43(4): 639-43.
40. Adaleti R, Nakipoglu Y, Ceran N, Tasdemir C, Kaya F, Tasdemir S. Prevalence of phenotypic resistance of Staphylococcus aureus isolates to macrolide, lincosamide, streptogramin B, ketolid and linezolid antibiotics in Turkey. Braz J Infect Dis 2010; 14(1): 11-4.
41. Mendes RE, Deshpande LM, Farrell DJ, Spanu T, Fadda C, Jones RN. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010; 65(11): 2329-35.
42. Sánchez García M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303(22): 2260-4.
43. Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents 2011; 37(3): 202-9.
44. th General Meeting of American Society for Microbiology. May 21-24, 2011, New Orleans, Louisiana. Abst No. C-100.
45. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 2010; 54(8): 3079-85.
46. Florescu I, Beuran M, Dimov R, et al; 307 Study Group. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62(Suppl 1): i17-28.
47. Shams W, Walker ES, Levy F, Reynolds SA, Peterson SM, Sarubbi FA. Comparative activity of telavancin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus isolates collected from 1991 to 2006. Chemotherapy 2010; 56(5): 411-6.
48. Zhanel GG, DeCorby M, Adam H, et al. Prevalence of antimicrobial- resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob Agents Chemother 2010; 54(11): 4684-93.
49. Akoǧlu H, Zarakolu P, Altun B, Unal S. Hacettepe Üniversitesi Erişkin Hastanesinde 2004-2005 yillannda izole edilen hastane kaynakli metisilin dirençli Staphylococcus aureus suşlannin epidemiyolojik ve moleküler özellikleri. Mikrobiyol Bul 2010; 44(3): 343-55.
50. Ünlü M, Vardar G, Yaǧmuroǧlu A, Yildirim D. Klinik örneklerden soyutlanan Staphylococcus aureus suşlanna tigesiklin etkinliǧi ANKEM 2009; 23(1): 13-6.
51. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm